congratulate! Resproly was awarded the 3rd Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology
On December 23, 2020, the 3rd Guangdong-Hong Kong-Macao Greater Bay Area Top 50 Biotechnology Innovative Enterprises Award Ceremony was held in Nansha, Guangzhou. More than 400...
Awarded! Resproly won the 5 million yuan settlement award for the 2nd China Hengqin Technology Entre
On December 13, 2020, in order to implement the spirit of the 'Guangdong-Hong Kong-Macao Greater Bay Area Development Plan Outline' and promote the moderately diversified economic ...
Resproly completes 50 million yuan A round of financing and enters Zhuhai International Health Port
On August 27, 2019, Zhuhai Ruisplei Biopharmaceutical Co., Ltd. (referred to as 'Respley' or the 'Company') held a round of financing signing and launching ceremony for entering th...
Hikma disrupted the US$3.5 billion Seretide® inhaler, Vectura received a US$11 million milestone, an
Congratulations to Hikma and Vectura's cooperation product Seretide generic drug FDA approval. This is the project started by our company's Dr. Chen Yongqi as the earliest em...
Resproly won the top three in the China Division of the 'Longmen Makers' Global Innovation and Entre
On April 14th, the 3rd 'Longmen Makers' Global Innovation and Entrepreneurship Competition-China Finals was held in Shenzhen Wuzhou Hotel. Wang Zhigang, Minister of Science and Tec...
Resproly successfully broke through and won the 'Second Prize' of the competition
On March 21, the 4th Three Innovation Competition organized by Tsinghua Alumni Association successfully concluded in Zhuhai Resort Hotel. This roadshow attracted a total of 13 Tsin...